Long-Term Safety and Efficacy of Dasatinib in the Treatment of Chronic-Phase Chronic Myeloid Leukemia Patients Resistant or Intolerant to Imatinib
Blood and Lymphatic Cancer: Targets and Therapy
doi 10.2147/blctt.s48319
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2014
Authors
Publisher
Informa UK Limited